HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences to launch continuous Glucose Monitoring devices Diasens, GlucoLive
Mar-12-2026

Zydus Lifesciences is planning to launch Diasens and GlucoLive, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence-powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time.

Zydus has partnered with Digicare Health Solutions (TatvaCare), a healthcare technology company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlip to provide AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault - all in a single mobile application. 

Diasens and GlucoLive will enable automatic streaming of glucose readings to the patient’s smartphone every three minutes - without manual scanning - ensuring uninterrupted capture, including overnight reading and in emergencies. Through TatvaCare’s GoodFlip app, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>